http://dx.doi.org/10.31703/giidr.2017(II-I).05
10.31703/giidr.2017(II-I).05
Published : Dec 2017
A Review on the Management of Chronic Hepatitis B and C Infection
Viral hepatitis B and Viral hepatitis C are one of the leading causes of disease and death in the present-day world. These viruses greatly affect the liver by causing inflammation, cirrhosis, fibrosis, hepatocellular carcinoma (HCC) and even causes the death of affected individuals. It requires highly cautious treatment to resolve complications associated with it, including abnormal levels of serological molecules of specific antigens, antibodies and liver enzymes. The treatment involves the use of antiviral agents that fight against viral antigens, reverses the progression of the disease and also prevents morbidity. Further reading takes towards the development of safe and effective antiviral agents and other regimens for lessening complications and ensuring patient compliance. Moreover, vaccines are also available that fight against the virus and act to prevent the emergence of viral hepatitis. Future developments are today in clinical trials to produce safer and efficacious agents to combat and prevent this disease.
-
Hepatitis, Disease, Hepatitis B, Hepatitis C, Infection, Infection Control, Treatment
-
(1) Marriam Zahid
Undergrad Student, Department of Pharmacy, Quaid-i-Azam University, Islamabad, Pakistan.
(2) Ayesha Hamid
Undergrad Student, Department of Pharmacy, Quaid-i-Azam University, Islamabad, Pakistan.
(3) Aleenah Asad
Undergrad Student, Department of Pharmacy, Quaid-i-Azam University, Islamabad, Pakistan.
(4) Mubashar Rehman
Assistant Professor, Department of Pharmacy, Quaid I Azam University, Islamabad, Pakistan.
- Abergel A, Asselah T, Metivier S, Kersey K, Jiang D, Mo H, et al. (2016). Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study. Lancet Infect Dis;16:459-464.
- Asselah T, Kowdley KV, Zadeikis N, Wang S, Hassanein T, Horsmans Y, et al. efficacy of glecaprevir/pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis. Clin Gastroenterol Hepatol 2018;16:417-426.
- Balistreri, W.F., Murray, K. F., Rosenthal, P., Bansal, S., Lin, C.H., & Kersey, K. et al. (2017). The safety and effectiveness of ledipasvir- sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection. Hepatology; 66:371-378
- Bortolotti, F., Cadrobbi, P., & Crivellaro, C. et al. (1990). Long-term outcome of chronic type B hepatitis in patients who acquire hepatitis B virus infection in childhood. Gastroenterology. 99:805-10.
- Bortolotti, F., Jara, P., & Crivellaro, C et al. (1998). Outcome of chronic hepatitis B in Caucasian children during a 20-year observation period. J Hepatol.;29:184-90.
- Buster, E. H., Hansen, B. E., Lau, G. K., Piratvisuth, T., Zeuzem, S., Steyerberg, E. W., & Janssen, H. L. (2009). Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology.137:2002-2009.
- Chae HB, Hann HW. Baseline HBV DNA level is the most important factor associated with virologic breakthrough in chronic hepatitis B treated with lamivudine. World J Gastroenterol. 2007;13:4085-4090.
- Chan HL, Hui AY, Wong ML, Tse AM, Hung LC, Wong VW, Sung JJ. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut. 2004;53:1494-8.
- Chang TT, Gish RG, de Man R al. et A comparison of entecavir and lamuvidine for HBe Ag- positive chronic hepatitis B. N. Engl. J . Med 2006; 354: 1001-10.
- Chang, T. T., Lai, C. L., Kew Yoon, S. al et. (2010). Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positivechronic hepatitis B. Hepatolog; 51: 422- 30.
- Dianzani F. Biological basis for the clinical use of interferon. Gut. 1993;34:S74-S76.
- El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142:1264-1273.
- Euler GL, Wooten KG, Baughman AL, Williams WW. Hepatitis B surface antigen prevalence among pregnant women in urban areas: implications for testing, reporting, and preventing perinatal transmission. Pediatrics. 2003;111:1192-7.
- European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol 2017;66:153- 194
- Fattovich G, Giustina G, Degos F, Diodati G, Tremolada F, Nevens F, Almasio P, et al. effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 1997;27:201-205.
- Feld JJ, Jacobson IM, Hezode C, Asselah T, Ruane PJ, Gruener N, et al. Sofosbuvir and velpatasvir for HCV gGenotype 1, 2, 4, 5, and 6 infection. N Engl J Med 2015;373:2599-2607.
- Foster GR, Afdhal N, Roberts SK, Brau N, Gane EJ, Pianko S, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 2015;373:2608-2617.
- Fried MW, Buti M, Dore GJ, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study. Hepatology. 2013;58(6):1918-1929.
- Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013;368(1):34-44.
- Gish RG, Chang TT, Lai CL al et. Loss of HBsAg antigen during treatment with entecavir or lamuvidine in nucleoside-naive HBe Ag- positive patients with chronic hepatitis B. J. Viral. Hepat. 2010; 17: 16-22.
- Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Wulfsohn MS, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med. 2003;348:800- 807.
- Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Ma J, et al. Long-term therapy with adefovir dipivoxil for HBeAg- negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006;131:1743- 1751.
- Hann HW, Gregory VL, Dixon JS, Barker KF. A review of the one-year incidence of resistance to lamivudine in the treatment of chronic hepatitis B: Lamivudine resistance. Hepatol Int. 2008;2:440-456.
- Hézode C, Forestier N, Dusheiko G, et al; PROVE2 Study Team. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009;360(18):1839-1850.
- Hill JB, Sheffield JS, Kim MJ, Alexander JM, Sercely B, Wendel GD. Risk of hepatitis B transmission in breast-fed infants of chronic hepatitis B carriers. Obstet Gynecol. 2002;99:1049.
- Jacobson IM, Gordon SC, Kowdley KV, et al; POSITRON Study; FUSION Study. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368(20):1867-1877.
- Jacobson IM, McHutchison JG, Dusheiko G, et al; ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405-2416
- Jonas MM, Block JM, Haber BA, et al. treatment of children with chronic hepatitis B virus infection in the United States: patient selection and therapeutic options. Hepatology. 2010;52:2192-205.
- Jonas MM, Kelly D, pollack H, et al. Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to
- Karino Y, Toyota J, Kinda H al et. efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamuvidine refractory chronic hepatitis B. Hepatol. Int. 2010; 4: 414-22.
- Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, Tobias H. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol. 2008;6:1315-141; quiz 1286.
- Kohli A, Kapoor R, Sims Z, Nelson A, Sidharthan S, Lam B, et al. Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of- concept, single-centre, open-label Phase 2a cohort study. Lancet Infect Dis 2015;15:1049-1054.
- Kwo P, Gane EJ, Peng CY, Pearlman B, Vierling JM, Serfaty L, et al. effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment- experienced patients with chronic hepatitis C infection. Gastroenterology 2017;152:164-175, e164.
- Kwo PY, Poordad F, Asatryan A, Wang S, Wyles DL, Hassanein T, et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol 2017;67:263-271.
- Lai CL, Gane E. Liaw VF al et. Telbivudine versus lamuvidine in patients with chronic hepatitis B. N. Engl. J. Med. 2007; 357: 25 76-88.
- Lai CL, Shouval D, Lok AS al et. entecavir versus lamuvidine for patients with HBe Ag- negative chronic hepatitis B. N. Engl. J. Med; 2006; 354: 1011-20. Seto WK, Lai CL. Fung J, Yuen J, Wong DKH, Yuen MF. A three year study on viral suppressions and resistance profile for treatment-naive CHB patients receiving continuous entecavir treatment. Hepatol. Int; 2010; 4: 58.
- Langley DR, Walsh AW, Baldick CJ al et. inhibition of hepatitis B virus polymerase by entecavir. J. virol. 2007; 81: 3992-4001.
- Lau DT, Everhart J, Kleiner DE, Park Y, Vergalla J, Schmid P, Hoofnagle JH. Long-term follow up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology. 1997;113:1660-1667.
- Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352:2682- 2695.
- Liaw YF, Gane E, Leung N al et.2-year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009 ; 136: 486-95.
- Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Chien RN, Dent J, Roman L, Edmundson S, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology. 2000;119:172-180.
- Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521-1531.
- Lim SG, Mohamed R, Le P, Tee HP, McNabb BL, Lu S, et al. safety and efficacy of sofosbuvir/velpatasvir in a genotype 1-6 HCV-infected population from Singapore, Malaysia, Thailand, and Vietnam: results from a Phase 3 clinical trial. Hepatology 2017;66:586A.
- Locarnini S, Qi W, Arterburn S. Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB) Hepatology. 2005;42:17A.
- Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661-662.
- Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958 -965.
- Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L, Goodman Z, Wulfsohn MS, Xiong S, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003;348:808-816.
- Mast EE, Hwang LY, Seto DS, Nolte FS, Nainan OV, Wurtzel H, et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis 2005;192:1880-1889.
- Muir AJ, Poordad FF, McHutchison JG, et al. Retreatment with telaprevir combination therapy in hepatitis C patients with well characterized prior treatment response. Hepatology. 2011;54(5):1538-1546.
- Osinusi A, Meissner EG, Lee YJ, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial.JAMA. 2013;310(8):804-811.
- Palumbo E. Hepatitis B genotypes and response to antiviral therapy: a review. Am J Ther. 2007;14:306-9.
- Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol. 2001;34:306-313.
- Perrillo R, Hann HW, Mutimer D, Willems B, Leung N, Lee WM, Moorat A, Gardner S, Woessner M, Bourne E, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology. 2004;126:81-90.
- Peters MG, Hann Hw Hw, Martin P, Heathcote EJ, Buggisch P, Rubin R, Bourliere M, Kowdley K, Trepo C, Gray Df Df, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine- resistant chronic hepatitis B. Gastroenterology. 2004;126:91-101.
- Poordad F, McCone J Jr, Bacon BR, et al; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195-1206.
- Robert G Gish, JY Lau, Linda Brooks, Jane WS Fang, Stephen L Steady, Joanne C Imperial, Richard Garcia-Kennedy, Carlos O Esquivel, Emmet B Keeffe Hepatology 1996;23 (1), 1-7.
- Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, et al. efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C- EDGE CO-INFECTION): a non- randomised, open-label trial. Lancet HIV 2015;2:e319-e327.
- Schuppan D, Afdhal NH. Liver cirrhosis. Lancet.2008;371:838-851.
- Seeff LB, Hoofnagle JH. National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. HEPATOLOGY 2002;36.
- Sherman KE, Flamm SL, Afdhal NH, et al; ILLUMINATE Study Team. Response- guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011;365(11):1014-1024.
- Strader DB, Seeff LB. The natural history of chronic hepatitis C infection. Eur J Gastroenterol Hepatol 1996;8:324 -328.
- Suzuki Y, Suzuki F, kawamura Y al et. efficacy of entecavir treatment for lamivudine- resistant hepatitis B over 3 years: histological improvement or entecavir resistance? J. Gastroebterol. Hepatol. 2009; 24: 429-35.
- Tenney DJ, Rose RE, Baldick CJ al et. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rae through 5 years of therapy. Hepatology 2009; 49: 1503-14
- Wiegand J, van Bömmel F, Berg T. Management of chronic hepatitis B: status and challenges beyond treatment guidelines. Semin Liver Dis. 2010;30:361-377.
- Xu DZ, Yan YP, Choi BC, et al. Risk factors and mechanism of transplacental transmission of hepatitis B virus: a case-control study. J Med Virol. 2002;67:20-618.
- Yuen MF, Kim J, Kim CR al et. A randomized placebo- controlled, dose-filling study of oral LB80380 in HBeAg- positive patients with chronic hepatitis B.Antivir,Ther,2006;11:977-83.
- Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology. 2001;34:785-791.
- Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ben Ari Z, Zhao Y, et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med 2015;163:1-13.
- Zoulim F, Perrillo R. Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol. 2008;48 Suppl 1:S2-19
Cite this article
-
APA : Zahid, M., Hamid, A., & Asad, A. (2017). A Review on the Management of Chronic Hepatitis B and C Infection. Global Immunological & Infectious Diseases Review, II(I), 59-62. https://doi.org/10.31703/giidr.2017(II-I).05
-
CHICAGO : Zahid, Marriam, Ayesha Hamid, and Aleenah Asad. 2017. "A Review on the Management of Chronic Hepatitis B and C Infection." Global Immunological & Infectious Diseases Review, II (I): 59-62 doi: 10.31703/giidr.2017(II-I).05
-
HARVARD : ZAHID, M., HAMID, A. & ASAD, A. 2017. A Review on the Management of Chronic Hepatitis B and C Infection. Global Immunological & Infectious Diseases Review, II, 59-62.
-
MHRA : Zahid, Marriam, Ayesha Hamid, and Aleenah Asad. 2017. "A Review on the Management of Chronic Hepatitis B and C Infection." Global Immunological & Infectious Diseases Review, II: 59-62
-
MLA : Zahid, Marriam, Ayesha Hamid, and Aleenah Asad. "A Review on the Management of Chronic Hepatitis B and C Infection." Global Immunological & Infectious Diseases Review, II.I (2017): 59-62 Print.
-
OXFORD : Zahid, Marriam, Hamid, Ayesha, and Asad, Aleenah (2017), "A Review on the Management of Chronic Hepatitis B and C Infection", Global Immunological & Infectious Diseases Review, II (I), 59-62
-
TURABIAN : Zahid, Marriam, Ayesha Hamid, and Aleenah Asad. "A Review on the Management of Chronic Hepatitis B and C Infection." Global Immunological & Infectious Diseases Review II, no. I (2017): 59-62. https://doi.org/10.31703/giidr.2017(II-I).05